scholarly journals EZH2 inhibition suppresses bladder cancer cell growth and metastasis via the JAK2/STAT3 signaling pathway

2019 ◽  
Author(s):  
Zhiyuan Chen ◽  
Yang Du ◽  
Xiuheng Liu ◽  
Hui Chen ◽  
Xiaodong Weng ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cell Growth ◽  
Signaling Pathway ◽  
Cancer Cell ◽  
Bladder Cancer Cell ◽  
Cancer Cell Growth ◽  
Stat3 Signaling ◽  
Stat3 Signaling Pathway

scholarly journals CCL18-NIR1 promotes oral cancer cell growth and metastasis by activating the JAK2/STAT3 signaling pathway

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Xiao Jiang ◽  
Zhijie Huang ◽  
Xiang Sun ◽  
Xianghuai Zheng ◽  
Jingpeng Liu ◽  
...  
Keyword(s):  
Cell Growth ◽  
Oral Cancer ◽  
Signaling Pathway ◽  
Cancer Cell ◽  
Cancer Cell Growth ◽  
Stat3 Signaling ◽  
Oral Cancer Cell ◽  
Stat3 Signaling Pathway

scholarly journals Enhanced Inhibition of Bladder Cancer Cell Growth by Simultaneous Knockdown of Antiapoptotic Bcl-xL and Survivin in Combination with Chemotherapy

2013 ◽  
Vol 14 (6) ◽  
pp. 12297-12312 ◽  
Author(s):  
Doreen Kunze ◽  
Kati Erdmann ◽  
Michael Froehner ◽  
Manfred Wirth ◽  
Susanne Fuessel
Keyword(s):  
Bladder Cancer ◽  
Cell Growth ◽  
Cancer Cell ◽  
Bladder Cancer Cell ◽  
Cancer Cell Growth

A natural product phillygenin suppresses osteosarcoma growth and metastasis by regulating the SHP-1/JAK2/STAT3 signaling

2021 ◽  
Vol 85 (2) ◽  
pp. 307-314
Author(s):  
Xiaomin Ding ◽  
Danqing Lu ◽  
Jianbo Fan
Keyword(s):  
Cell Growth ◽  
Signaling Pathway ◽  
Janus Kinase ◽  
Potential Candidate ◽  
Osteosarcoma Cell ◽  
Cancer Cell Growth ◽  
Functional Roles ◽  
Stat3 Signaling ◽  
Stat3 Signaling Pathway

ABSTRACT Osteosarcoma represents one of the most devastating cancers due to its high metastatic potency and fatality. Osteosarcoma is insensitive to traditional chemotherapy. Identification of a small molecule that blocks osteosarcoma progression has been a challenge in drug development. Phillygenin, a plant-derived tetrahydrofurofuran lignin, has shown to suppress cancer cell growth and inflammatory response. However, how phillygenin plays functional roles in osteosarcoma has remained unveiled. In this study, we showed that phillygenin inhibited osteosarcoma cell growth and motility in vitro. Further mechanistic studies indicated that phillygenin blocked STAT3 signaling pathway. Phillygenin led to significant downregulation of Janus kinase 2 and upregulation of Src homology region 2 domain-containing phosphatase 1. Gene products of STAT3 regulating cell survival and invasion were also inhibited by phillygenin. Therefore, our studies provided the first evidence that phillygenin repressed osteosarcoma progression by interfering STAT3 signaling pathway. Phillygenin is a potential candidate in osteosarcoma therapy.

Sign in / Sign up

Export Citation Format

Share Document